MYNZ
Mainz Biomed N.V.1.0000
-0.0200-1.96%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
8.58MP/E (TTM)
-Basic EPS (TTM)
-5.28Dividend Yield
0%Recent Filings
10-K
FY2025 results
Mainz Biomed's FY2025 revenue fell 40% y/y to $537K from ColoAlert sales in Europe, with gross margins expanding to 73% from 64% as direct-to-consumer wound down. Operating loss narrowed 14% to $16.1M amid 15% opex cuts, though a $2.6M intangible impairment hit. Cash drained to $889K by year-end, offset by $6.8M financing inflows. Q4 saw strategic pivot: colorectal programs axed, ColoAlert IP sold March 2026, focus shifts to pancreatic screening and cybersecurity. Cash burn slowed. Going concern looms large.
8-K
Nasdaq bid price warning
Mainz Biomed received a Nasdaq deficiency notice on March 20, 2026, for failing the $1.00 minimum bid price over 30 business days ending March 19. Shares get 180 days until September 16 to close at or above $1.00 for 10 straight business days. No immediate delisting; trading continues. A reverse split looms if needed.
8-K
Aligns with Trump cyber strategy
Quantum Cyber aligned its strategy with the Trump Administration's National Cybersecurity Strategy released March 10, 2026, targeting acquisitions in quantum computing and cyber defense sectors. Shareholder David Lazar pre-funded the $3M second tranche of a private placement on March 17, 2026, bringing total investment to $6M; closing awaits shareholder approval and conditions before April 2026. No deals signed yet. Risks include approval failure.
8-K
Liscouski named Chairman; ticker to QUCY
Mainz Biomed appointed Robert P. Liscouski, cybersecurity expert and Quantum Computing Inc. co-founder, as Chairman on March 11, 2026, term through April EGM. Shares switch to QUCY ticker and 'Quantum Cyber' branding March 12. New punchy cybersecurity pivot sharpens focus amid colorectal asset sale plans. Forward-looking risks include execution hurdles.
8-K
Lazar invests $3M, eyes control
Mainz Biomed closed a $3M first tranche private placement on February 13, 2026, issuing 3M preferred shares convertible into 27M ordinary shares to David Lazar, who joined as board chair. A second $3M tranche awaits shareholder approval by April 15 for shares convertible into 450M ordinary shares, potentially giving Lazar 95% control on dilution. Proceeds fund operations; settlements total $1.9M. Lazar grabs the reins.
BNR
Burning Rock Biotech Limited
18.74+2.98
CHEK
Check-Cap Ltd.
1.61+0.03
CODX
Co-Diagnostics, Inc.
0.25-0.02
EXAS
Exact Sciences Corporation
101.76+0.02
GNTLF
GENETIC TECHNOLOGIES
1.00+0.00
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
IMDX
Insight Molecular Diagnostics I
5.10+0.08
MYGN
Myriad Genetics, Inc.
6.88-0.11
NEO
NeoGenomics, Inc.
11.67-0.25